董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Roderick H. O'Reilly | 男 | Chair of the board | 61 | 未披露 | 未持股 | 2023-06-19 |
| Jason Krikorian | 男 | Director | 51 | 15.42万美元 | 未持股 | 2023-06-19 |
| Joseph Marks | 男 | Director | 65 | 14.00万美元 | 未持股 | 2023-06-19 |
| Margie Traylor | 女 | Director | 59 | 18.76万美元 | 未持股 | 2023-06-19 |
| Emmanuel Krakaris | 男 | President, Chief Executive Officer, Secretary,Director | 64 | 115.75万美元 | 未持股 | 2023-06-19 |
| Ian Shakil | 男 | Chief Strategy Officer and Director | 39 | 未披露 | 未持股 | 2023-06-19 |
| Robert Faulkner | 男 | Director | 60 | 未披露 | 未持股 | 2023-06-19 |
| Laurie A.S. McGraw | 女 | Director | 59 | 17.84万美元 | 未持股 | 2023-06-19 |
| William J. Febbo | 男 | Director | 54 | 22.47万美元 | 未持股 | 2023-06-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Emmanuel Krakaris | 男 | President, Chief Executive Officer, Secretary,Director | 64 | 115.75万美元 | 未持股 | 2023-06-19 |
| Sandra Breber | 女 | Chief Operating Officer | 65 | 73.64万美元 | 未持股 | 2023-06-19 |
| Saurav Chatterjee | 男 | Chief Technology Officer | 52 | 63.34万美元 | 未持股 | 2023-06-19 |
| Jonathan Hawkins | 男 | Chief Revenue Officer | 53 | 44.00万美元 | 未持股 | 2023-06-19 |
| Paul Ginocchio | 男 | Chief Financial Officer | 54 | 未披露 | 未持股 | 2023-06-19 |
| Ian Shakil | 男 | Chief Strategy Officer and Director | 39 | 未披露 | 未持股 | 2023-06-19 |
董事简历
中英对照 | 中文 | 英文- Roderick H. O'Reilly
-
RoderickH.O’Reilly是Change梦百合的执行Vice President兼软件和分析总裁。在加入Change梦百合之前，O’；Reilly先生于2014年10月至2017年3月交易完成期间担任MHS总裁。在担任该职位之前，O’；Reilly从2013年3月到2014年10月担任MTS战略和业务发展高级副总裁，领导投资组合管理、并购和综合规划。O’；Reilly从2010年到2013年还担任McKesson’；s Health Systems Enterprise Solutions总裁。在此之前，O’；Reilly从2008年到2010年担任Enterprise Medical Imaging Group总裁。O’；Reilly先生于2002年通过收购A.L.I.Technologies加入McKesson，他自1998年以来一直担任该公司的运营Vice President。O&；8217；Reilly先生在Simon Fraser大学获得工商管理学士学位，在British Columbia大学获得工商管理硕士学位。
Roderick H. O'Reilly is Change Healthcare Inc. Executive Vice President and President, Software and Analytics. Prior to joining Change Healthcare Inc., Mr. O'Reilly served as President of McKesson Health Solutions from October 2014 to the closing of the Joint Venture in March 2017. Prior to that position, Mr. O'Reilly led portfolio management, mergers and acquisitions and integrated planning as the Senior Vice President of Strategy and Business Development for McKesson Technology Solutions from March 2013 to October 2014. Mr. O'Reilly also served as President of McKesson's Health Systems Enterprise Solutions from 2010 to 2013. Prior to that, Mr. O'Reilly was President of the Enterprise Medical Imaging Group from 2008 to 2010. Mr. O'Reilly joined McKesson in 2002 through the acquisition of A.L.I. Technologies, where he had served as Vice President of Operations since 1998. Mr. O'Reilly earned his B.A. in Business Administration from Simon Fraser University and his M.B.A. from the University of British Columbia. - RoderickH.O’Reilly是Change梦百合的执行Vice President兼软件和分析总裁。在加入Change梦百合之前，O’；Reilly先生于2014年10月至2017年3月交易完成期间担任MHS总裁。在担任该职位之前，O’；Reilly从2013年3月到2014年10月担任MTS战略和业务发展高级副总裁，领导投资组合管理、并购和综合规划。O’；Reilly从2010年到2013年还担任McKesson’；s Health Systems Enterprise Solutions总裁。在此之前，O’；Reilly从2008年到2010年担任Enterprise Medical Imaging Group总裁。O’；Reilly先生于2002年通过收购A.L.I.Technologies加入McKesson，他自1998年以来一直担任该公司的运营Vice President。O&；8217；Reilly先生在Simon Fraser大学获得工商管理学士学位，在British Columbia大学获得工商管理硕士学位。
- Roderick H. O'Reilly is Change Healthcare Inc. Executive Vice President and President, Software and Analytics. Prior to joining Change Healthcare Inc., Mr. O'Reilly served as President of McKesson Health Solutions from October 2014 to the closing of the Joint Venture in March 2017. Prior to that position, Mr. O'Reilly led portfolio management, mergers and acquisitions and integrated planning as the Senior Vice President of Strategy and Business Development for McKesson Technology Solutions from March 2013 to October 2014. Mr. O'Reilly also served as President of McKesson's Health Systems Enterprise Solutions from 2010 to 2013. Prior to that, Mr. O'Reilly was President of the Enterprise Medical Imaging Group from 2008 to 2010. Mr. O'Reilly joined McKesson in 2002 through the acquisition of A.L.I. Technologies, where he had served as Vice President of Operations since 1998. Mr. O'Reilly earned his B.A. in Business Administration from Simon Fraser University and his M.B.A. from the University of British Columbia.
- Jason Krikorian
-
Jason Krikorian自2017年5月起担任我们的董事会成员。他目前也是DCM的普通合伙人（2010年7月以来）。在加入DCM之前，Krikorian先生共同创立了Sling Media，Inc.，这是一家数字媒体和设备公司。Krikorian先生拥有加州大学伯克利分校的心理学学士学位，弗吉尼亚大学法学院的法学博士学位和弗吉尼亚大学达顿商学院的工商管理硕士学位。
Jason Krikorian,has served as a member of Augmedix, Inc. board of directors since May 2017. He served as a General Partner of DCM, an international venture capital firm, from 2010 to December 2022. He has been a member of the board of directors of Matterport, Inc. since June 2014, Shift Technologies, Inc. since September 2018 and Playstudios, Inc. since June 2021. Prior to joining DCM, Mr. Krikorian co-founded Sling Media, Inc., a digital media and device company. Mr. Krikorian holds a B.A. in Psychology from the University of California, Berkeley, a J.D. from the University of Virginia School of Law, and a M.B.A. from the University of Virginia Darden School of Business. - Jason Krikorian自2017年5月起担任我们的董事会成员。他目前也是DCM的普通合伙人（2010年7月以来）。在加入DCM之前，Krikorian先生共同创立了Sling Media，Inc.，这是一家数字媒体和设备公司。Krikorian先生拥有加州大学伯克利分校的心理学学士学位，弗吉尼亚大学法学院的法学博士学位和弗吉尼亚大学达顿商学院的工商管理硕士学位。
- Jason Krikorian,has served as a member of Augmedix, Inc. board of directors since May 2017. He served as a General Partner of DCM, an international venture capital firm, from 2010 to December 2022. He has been a member of the board of directors of Matterport, Inc. since June 2014, Shift Technologies, Inc. since September 2018 and Playstudios, Inc. since June 2021. Prior to joining DCM, Mr. Krikorian co-founded Sling Media, Inc., a digital media and device company. Mr. Krikorian holds a B.A. in Psychology from the University of California, Berkeley, a J.D. from the University of Virginia School of Law, and a M.B.A. from the University of Virginia Darden School of Business.
- Joseph Marks
-
Joseph Marks自2020年1月起担任我们的董事会成员。他目前还是数字视觉效果公司Weta Digital Ltd.的首席技术官，自2020年9月以来一直在该公司任职。Marks博士也是卡内基梅隆大学机器学习与健康中心的执行主任，自2016年5月以来一直在该中心任职。Mark博士于2018年4月共同创立了Caboodle Technologies，Inc.。在此之前，Marks博士是位于爱尔兰都柏林的Upfront Analytics，Ltd的联合创始人。在职业生涯的早期，Marks博士曾担任研究科学家，然后从1993年到2006年担任三菱电机研究实验室的研究总监。马克斯博士拥有哈佛大学的应用数学学士学位，以及科学硕士和计算机科学博士学位。
Joseph Marks,is also currently a Class I director on Augmedix, Inc. board of directors. Mr. Marks has notified the Company that he will resign from Augmedix, Inc. board of directors effective as of the date of the Company's 2023 Annual Meeting of Stockholders. Mr. Marks plans to continue to advise the Company after his departure from the board of directors by serving as chair of the Company's AI advisory council. - Joseph Marks自2020年1月起担任我们的董事会成员。他目前还是数字视觉效果公司Weta Digital Ltd.的首席技术官，自2020年9月以来一直在该公司任职。Marks博士也是卡内基梅隆大学机器学习与健康中心的执行主任，自2016年5月以来一直在该中心任职。Mark博士于2018年4月共同创立了Caboodle Technologies，Inc.。在此之前，Marks博士是位于爱尔兰都柏林的Upfront Analytics，Ltd的联合创始人。在职业生涯的早期，Marks博士曾担任研究科学家，然后从1993年到2006年担任三菱电机研究实验室的研究总监。马克斯博士拥有哈佛大学的应用数学学士学位，以及科学硕士和计算机科学博士学位。
- Joseph Marks,is also currently a Class I director on Augmedix, Inc. board of directors. Mr. Marks has notified the Company that he will resign from Augmedix, Inc. board of directors effective as of the date of the Company's 2023 Annual Meeting of Stockholders. Mr. Marks plans to continue to advise the Company after his departure from the board of directors by serving as chair of the Company's AI advisory council.
- Margie Traylor
-
Margie Traylor自2021年5月起担任我们的董事会成员。Traylor是Audacious Studios（August United的母公司）的联合创始人，August United是一家有影响力的营销机构，Tailwind是一家绩效媒体咨询公司，Cast&Hue是一家体验设计咨询公司，Interobang是Interobang的母公司，在过去的22年里，她一直担任该公司的首席执行官。Traylor女士也是HonorHealth（一家非营利性医疗保健系统）的董事会成员，并在其战略规划，执行和薪酬，质量，审计和医务人员计划和合作委员会任职。Traylor女士拥有亚利桑那州立大学护理和健康创新学院的医疗保健创新硕士学位，以及亚利桑那州立大学W.P.Carey商学院的会计学士学位。她之前担任的公司领导职务包括电子商务副总裁、财务总监、普华永道审计师，以及上市和私人公司的注册会计师，收入在5亿美元至50亿美元之间。
Margie Traylor,has served as a member of Augmedix, Inc. board of directors since May 2021. Ms. Traylor co-founded August United, an influencer marketing agency and Tailwind, a performance media consultancy that were sold to Cheil Worldwide in 2022. Ms. Traylor previously served for 14 years as a board member of HonorHealth, a non-profit healthcare system, and serves on its Strategic Planning, Executive and Compensation, Quality, Audit and Medical Staff Planning and Partnership Committees. Ms. Traylor holds a Master of Healthcare Innovation from the Arizona State University College of Nursing and Health Innovation and a B.S. in Accounting from the Arizona State University, W. P. Carey School of Business. Her prior corporate leadership roles include E-Commerce Vice President, Controller, PwC Auditor, and CPA for public and private companies with $500M to $5B in revenues. - Margie Traylor自2021年5月起担任我们的董事会成员。Traylor是Audacious Studios（August United的母公司）的联合创始人，August United是一家有影响力的营销机构，Tailwind是一家绩效媒体咨询公司，Cast&Hue是一家体验设计咨询公司，Interobang是Interobang的母公司，在过去的22年里，她一直担任该公司的首席执行官。Traylor女士也是HonorHealth（一家非营利性医疗保健系统）的董事会成员，并在其战略规划，执行和薪酬，质量，审计和医务人员计划和合作委员会任职。Traylor女士拥有亚利桑那州立大学护理和健康创新学院的医疗保健创新硕士学位，以及亚利桑那州立大学W.P.Carey商学院的会计学士学位。她之前担任的公司领导职务包括电子商务副总裁、财务总监、普华永道审计师，以及上市和私人公司的注册会计师，收入在5亿美元至50亿美元之间。
- Margie Traylor,has served as a member of Augmedix, Inc. board of directors since May 2021. Ms. Traylor co-founded August United, an influencer marketing agency and Tailwind, a performance media consultancy that were sold to Cheil Worldwide in 2022. Ms. Traylor previously served for 14 years as a board member of HonorHealth, a non-profit healthcare system, and serves on its Strategic Planning, Executive and Compensation, Quality, Audit and Medical Staff Planning and Partnership Committees. Ms. Traylor holds a Master of Healthcare Innovation from the Arizona State University College of Nursing and Health Innovation and a B.S. in Accounting from the Arizona State University, W. P. Carey School of Business. Her prior corporate leadership roles include E-Commerce Vice President, Controller, PwC Auditor, and CPA for public and private companies with $500M to $5B in revenues.
- Emmanuel Krakaris
-
Emmanuel Krakaris自2018年10月起担任我们的总裁，首席执行官，秘书和董事会成员。在Krakaris先生被任命为我们的总裁，首席执行官兼秘书之前，Krakaris先生于2018年4月至2018年5月担任董事会顾问，并于2018年6月至2018年9月担任我们的首席运营官。在加入我们之前，Krakaris先生于2014年8月至2018年2月担任Streetline，Inc.的首席执行官，并于2011年至2014年8月担任首席财务官兼首席运营官。从1996年到2011年，Krakaris先生还担任Command Audio Corporation的首席财务官。Krakaris先生获得了麦吉尔大学市场营销和国际商务的商业学士学位，以及加州大学伯克利分校哈斯商学院的工商管理硕士学位。
Emmanuel Krakaris,has served as Augmedix, Inc. President, Chief Executive Officer, Secretary and as a member of Augmedix, Inc. board of directors since October 2018. Before Mr. Krakaris was appointed as Augmedix, Inc. President, Chief Executive Officer and Secretary, Mr. Krakaris served as an advisor to the board of directors from April 2018 to May 2018 and as Augmedix, Inc. Chief Operating Officer from June 2018 to September 2018. Prior to joining Augmedix, Inc. , Mr. Krakaris served as the Chief Executive Officer of Streetline, Inc. from August 2014 to February 2018 and as Chief Financial Officer and Chief Operating Officer from 2011 to August 2014. Mr. Krakaris also served as Chief Financial Officer of Command Audio Corporation from 1996 to 2011. Mr. Krakaris received a Bachelor of Commerce in Marketing and International Business from McGill University, and a M.B.A. from the University of California, Berkeley, Haas School of Business. - Emmanuel Krakaris自2018年10月起担任我们的总裁，首席执行官，秘书和董事会成员。在Krakaris先生被任命为我们的总裁，首席执行官兼秘书之前，Krakaris先生于2018年4月至2018年5月担任董事会顾问，并于2018年6月至2018年9月担任我们的首席运营官。在加入我们之前，Krakaris先生于2014年8月至2018年2月担任Streetline，Inc.的首席执行官，并于2011年至2014年8月担任首席财务官兼首席运营官。从1996年到2011年，Krakaris先生还担任Command Audio Corporation的首席财务官。Krakaris先生获得了麦吉尔大学市场营销和国际商务的商业学士学位，以及加州大学伯克利分校哈斯商学院的工商管理硕士学位。
- Emmanuel Krakaris,has served as Augmedix, Inc. President, Chief Executive Officer, Secretary and as a member of Augmedix, Inc. board of directors since October 2018. Before Mr. Krakaris was appointed as Augmedix, Inc. President, Chief Executive Officer and Secretary, Mr. Krakaris served as an advisor to the board of directors from April 2018 to May 2018 and as Augmedix, Inc. Chief Operating Officer from June 2018 to September 2018. Prior to joining Augmedix, Inc. , Mr. Krakaris served as the Chief Executive Officer of Streetline, Inc. from August 2014 to February 2018 and as Chief Financial Officer and Chief Operating Officer from 2011 to August 2014. Mr. Krakaris also served as Chief Financial Officer of Command Audio Corporation from 1996 to 2011. Mr. Krakaris received a Bachelor of Commerce in Marketing and International Business from McGill University, and a M.B.A. from the University of California, Berkeley, Haas School of Business.
- Ian Shakil
-
Ian Shakil是我们的创始人，自2013年4月起担任我们的董事会成员。他曾于2018年8月至2020年9月担任我们的董事会主席，自2018年10月以来一直担任我们的首席战略官。在此之前，Shakil先生于2013年4月至2018年10月担任我们的首席执行官。Shakil先生自2019年5月以来还担任爱德华兹生命科学公司的顾问。Shakil先生在杜克大学获得生物医学工程学士学位，并在斯坦福大学商学院获得工商管理硕士学位。我们相信Shakil先生有资格在我们的董事会任职，因为他是我们的创始人和前首席执行官，以及他在医疗保健行业的业务和技术经验。
Ian Shakil,is Augmedix, Inc. founder and has been a member of Augmedix, Inc. board of directors since April 2013. He previously served as Chairman of Augmedix, Inc. board of directors from August 2018 to September 2020 and has served as Augmedix, Inc. Chief Strategy Officer since October 2018. Prior to that, Mr. Shakil served as Augmedix, Inc. Chief Executive Officer from April 2013 to October 2018. Mr. Shakil has also served as Advisor to Edwards Lifesciences Corporation since May 2019. Mr. Shakil has a B.S.E. in Biomedical Engineering from Duke University, and an M.B.A. from Stanford University Graduate School of Business. - Ian Shakil是我们的创始人，自2013年4月起担任我们的董事会成员。他曾于2018年8月至2020年9月担任我们的董事会主席，自2018年10月以来一直担任我们的首席战略官。在此之前，Shakil先生于2013年4月至2018年10月担任我们的首席执行官。Shakil先生自2019年5月以来还担任爱德华兹生命科学公司的顾问。Shakil先生在杜克大学获得生物医学工程学士学位，并在斯坦福大学商学院获得工商管理硕士学位。我们相信Shakil先生有资格在我们的董事会任职，因为他是我们的创始人和前首席执行官，以及他在医疗保健行业的业务和技术经验。
- Ian Shakil,is Augmedix, Inc. founder and has been a member of Augmedix, Inc. board of directors since April 2013. He previously served as Chairman of Augmedix, Inc. board of directors from August 2018 to September 2020 and has served as Augmedix, Inc. Chief Strategy Officer since October 2018. Prior to that, Mr. Shakil served as Augmedix, Inc. Chief Executive Officer from April 2013 to October 2018. Mr. Shakil has also served as Advisor to Edwards Lifesciences Corporation since May 2019. Mr. Shakil has a B.S.E. in Biomedical Engineering from Duke University, and an M.B.A. from Stanford University Graduate School of Business.
- Robert Faulkner
-
罗伯特·福克纳，自2023年4月起担任Augmedix，Inc.董事会成员。福克纳先生自2008年2月以来一直担任Redmile Group，LLC的董事总经理，该公司是一家专注于医疗保健的投资公司。福克纳先生自2020年11月起担任MedAvail Holdings公司（“MedAvail”）董事会成员，自2022年1月起担任MedAvail公司董事会主席，自2021年10月起担任Science 37 Holdings公司董事会主席。在加入Redmile之前，从1992年到2008年，福克纳曾在Hambrecht & Quist（现在的摩根大通）、Thomas Weisel Partners（现在的Stifel Financial Corp.）和SG Warburg & Co（现在的瑞银）担任了16年的卖方股票分析师。福克纳拥有哈佛大学的学士学位和达特茅斯学院塔克商学院的工商管理硕士学位。
Robert Faulkner,has served as a member of Augmedix, Inc. board of directors since April 2023. Mr. Faulkner has been a Managing Director at Redmile Group, LLC, a health care-focused investment firm, since February 2008. Mr. Faulkner has served on the board of directors of MedAvail Holdings, Inc. ("MedAvail") since November 2020 and as chairman of MedAvail's board of directors since January 2022, as well as the Chairman of the board of directors of Science 37 Holdings, Inc. since October 2021. Prior to Redmile, Mr. Faulkner was a sell-side equity analyst for 16 years, from 1992 to 2008, including at Hambrecht & Quist (now JPMorgan), Thomas Weisel Partners (now Stifel Financial Corp.) and SG Warburg & Co. (now UBS). Mr. Faulkner holds an A.B. from Harvard College and an M.B.A. from the Tuck School of Business at Dartmouth College. - 罗伯特·福克纳，自2023年4月起担任Augmedix，Inc.董事会成员。福克纳先生自2008年2月以来一直担任Redmile Group，LLC的董事总经理，该公司是一家专注于医疗保健的投资公司。福克纳先生自2020年11月起担任MedAvail Holdings公司（“MedAvail”）董事会成员，自2022年1月起担任MedAvail公司董事会主席，自2021年10月起担任Science 37 Holdings公司董事会主席。在加入Redmile之前，从1992年到2008年，福克纳曾在Hambrecht & Quist（现在的摩根大通）、Thomas Weisel Partners（现在的Stifel Financial Corp.）和SG Warburg & Co（现在的瑞银）担任了16年的卖方股票分析师。福克纳拥有哈佛大学的学士学位和达特茅斯学院塔克商学院的工商管理硕士学位。
- Robert Faulkner,has served as a member of Augmedix, Inc. board of directors since April 2023. Mr. Faulkner has been a Managing Director at Redmile Group, LLC, a health care-focused investment firm, since February 2008. Mr. Faulkner has served on the board of directors of MedAvail Holdings, Inc. ("MedAvail") since November 2020 and as chairman of MedAvail's board of directors since January 2022, as well as the Chairman of the board of directors of Science 37 Holdings, Inc. since October 2021. Prior to Redmile, Mr. Faulkner was a sell-side equity analyst for 16 years, from 1992 to 2008, including at Hambrecht & Quist (now JPMorgan), Thomas Weisel Partners (now Stifel Financial Corp.) and SG Warburg & Co. (now UBS). Mr. Faulkner holds an A.B. from Harvard College and an M.B.A. from the Tuck School of Business at Dartmouth College.
- Laurie A.S. McGraw
-
Laurie A.S. McGraw，自2022年3月起担任Augmedix，Inc.董事会成员。McGraw女士曾担任美国医学协会（American Medical Associations，简称“AMA”）下属部门Health Solutions的高级副总裁，负责AMA的数据解决方案Augmedix，Inc.，负责整个医疗保健行业的创新和标准制定，她于2016年2月至2022年3月担任该职位。麦格劳女士是MedAvail Holdings公司的董事会成员。从2013年到2015年，麦格劳女士担任临床文档和数据解决方案公司Shareable Ink的首席执行官。从2000年到2013年，McGraw女士在Allscripts担任过各种领导职务，包括企业解决方案总裁和首席客户官。她加入Allscripts的时候，Allscripts是一家价值3000万美元的公司，并带领该公司成长为一家价值15亿美元的公司。在出售给Allscripts之前，McGraw女士还在ChannelHealth/IDX担任了十年的开发领导和客户成功主管。麦格劳获得了布朗大学的荣誉理学学士学位。
Laurie A.S. McGraw,has served as a member of Augmedix, Inc. board of directors since March 2022. Ms. McGraw served as Senior Vice President, Health Solutions, a division of the American Medical Associations ("AMA"), where she was responsible for AMA's data solutions Augmedix, Inc. ed for innovation and standard-setting across the entire healthcare industry, which is a position she held from February 2016 to March 2022. Ms. McGraw serves on the board of MedAvail Holdings, Inc. From 2013 to 2015, Ms. McGraw served as Chief Executive Officer of Shareable Ink, a clinical documentation and data solutions company. From 2000 to 2013, Ms. McGraw served in various leadership roles at Allscripts including President, Enterprise Solutions and Chief Client Officer. She joined Allscripts when it was a $30 million company and oversaw its growth into a $1.5 billion company. Ms. McGraw also spent ten years as a development leader and head of client success at ChannelHealth/IDX before its sale to Allscripts. Ms. McGraw received a Sc. B. with honors from Brown University. - Laurie A.S. McGraw，自2022年3月起担任Augmedix，Inc.董事会成员。McGraw女士曾担任美国医学协会（American Medical Associations，简称“AMA”）下属部门Health Solutions的高级副总裁，负责AMA的数据解决方案Augmedix，Inc.，负责整个医疗保健行业的创新和标准制定，她于2016年2月至2022年3月担任该职位。麦格劳女士是MedAvail Holdings公司的董事会成员。从2013年到2015年，麦格劳女士担任临床文档和数据解决方案公司Shareable Ink的首席执行官。从2000年到2013年，McGraw女士在Allscripts担任过各种领导职务，包括企业解决方案总裁和首席客户官。她加入Allscripts的时候，Allscripts是一家价值3000万美元的公司，并带领该公司成长为一家价值15亿美元的公司。在出售给Allscripts之前，McGraw女士还在ChannelHealth/IDX担任了十年的开发领导和客户成功主管。麦格劳获得了布朗大学的荣誉理学学士学位。
- Laurie A.S. McGraw,has served as a member of Augmedix, Inc. board of directors since March 2022. Ms. McGraw served as Senior Vice President, Health Solutions, a division of the American Medical Associations ("AMA"), where she was responsible for AMA's data solutions Augmedix, Inc. ed for innovation and standard-setting across the entire healthcare industry, which is a position she held from February 2016 to March 2022. Ms. McGraw serves on the board of MedAvail Holdings, Inc. From 2013 to 2015, Ms. McGraw served as Chief Executive Officer of Shareable Ink, a clinical documentation and data solutions company. From 2000 to 2013, Ms. McGraw served in various leadership roles at Allscripts including President, Enterprise Solutions and Chief Client Officer. She joined Allscripts when it was a $30 million company and oversaw its growth into a $1.5 billion company. Ms. McGraw also spent ten years as a development leader and head of client success at ChannelHealth/IDX before its sale to Allscripts. Ms. McGraw received a Sc. B. with honors from Brown University.
- William J. Febbo
-
WilliamJ.Febbo于2016年2月22日加入本公司，担任首席执行官兼董事。在加入我们公司之前。从2007年到2015年，他在投资银行公司MerrimanHoldings，Inc.工作。在那里他曾担任首席运营官，并协助技术、生物技术、清洁技术、消费者和资源行业的资本筹集。在Merriman之前，Febbo先生是MedPanel的首席执行官兼联合创始人，MedPanel是一家为制药，生物医学和医疗器械行业提供市场情报和通信的提供商，该公司最终被MCF Corporation收购。
William J. Febbo currently serves as Chief Executive Officer and Director of Performance Health Systems, a privately held company that utilizes health and wellness equipment to improve mobility for people at home, businesses, and clinics, which he joined in February 2026. Previously, he served as Chief Executive Officer of OptimizeRx Corporation (NASDAQ: OPRX) from 2015 to 2024, where he transformed the company from a single point of care product provider into an AI driven omnichannel platform. Under his leadership, revenue grew from $5 million to $92 million, achieving a five year CAGR of 41%. He also led OptimizeRx's uplisting from OTC to Nasdaq and expanded its digital healthcare network, contributing to significant growth in its market capitalization. Mr. Febbo has also co founded and led companies focused on the capital markets, including Merriman Holdings, Inc., and Digital Capital Network. Mr. Febbo received a BA in International Studies and Spanish from Dickinson College. He is an MIT affiliated faculty member and mentor in the linQ program, supporting biomedical innovations addressing major health and medical challenges. He also in a Mentor for the X & Y Class at Harvard Business School. - WilliamJ.Febbo于2016年2月22日加入本公司，担任首席执行官兼董事。在加入我们公司之前。从2007年到2015年，他在投资银行公司MerrimanHoldings，Inc.工作。在那里他曾担任首席运营官，并协助技术、生物技术、清洁技术、消费者和资源行业的资本筹集。在Merriman之前，Febbo先生是MedPanel的首席执行官兼联合创始人，MedPanel是一家为制药，生物医学和医疗器械行业提供市场情报和通信的提供商，该公司最终被MCF Corporation收购。
- William J. Febbo currently serves as Chief Executive Officer and Director of Performance Health Systems, a privately held company that utilizes health and wellness equipment to improve mobility for people at home, businesses, and clinics, which he joined in February 2026. Previously, he served as Chief Executive Officer of OptimizeRx Corporation (NASDAQ: OPRX) from 2015 to 2024, where he transformed the company from a single point of care product provider into an AI driven omnichannel platform. Under his leadership, revenue grew from $5 million to $92 million, achieving a five year CAGR of 41%. He also led OptimizeRx's uplisting from OTC to Nasdaq and expanded its digital healthcare network, contributing to significant growth in its market capitalization. Mr. Febbo has also co founded and led companies focused on the capital markets, including Merriman Holdings, Inc., and Digital Capital Network. Mr. Febbo received a BA in International Studies and Spanish from Dickinson College. He is an MIT affiliated faculty member and mentor in the linQ program, supporting biomedical innovations addressing major health and medical challenges. He also in a Mentor for the X & Y Class at Harvard Business School.
高管简历
中英对照 | 中文 | 英文- Emmanuel Krakaris
Emmanuel Krakaris自2018年10月起担任我们的总裁，首席执行官，秘书和董事会成员。在Krakaris先生被任命为我们的总裁，首席执行官兼秘书之前，Krakaris先生于2018年4月至2018年5月担任董事会顾问，并于2018年6月至2018年9月担任我们的首席运营官。在加入我们之前，Krakaris先生于2014年8月至2018年2月担任Streetline，Inc.的首席执行官，并于2011年至2014年8月担任首席财务官兼首席运营官。从1996年到2011年，Krakaris先生还担任Command Audio Corporation的首席财务官。Krakaris先生获得了麦吉尔大学市场营销和国际商务的商业学士学位，以及加州大学伯克利分校哈斯商学院的工商管理硕士学位。
Emmanuel Krakaris,has served as Augmedix, Inc. President, Chief Executive Officer, Secretary and as a member of Augmedix, Inc. board of directors since October 2018. Before Mr. Krakaris was appointed as Augmedix, Inc. President, Chief Executive Officer and Secretary, Mr. Krakaris served as an advisor to the board of directors from April 2018 to May 2018 and as Augmedix, Inc. Chief Operating Officer from June 2018 to September 2018. Prior to joining Augmedix, Inc. , Mr. Krakaris served as the Chief Executive Officer of Streetline, Inc. from August 2014 to February 2018 and as Chief Financial Officer and Chief Operating Officer from 2011 to August 2014. Mr. Krakaris also served as Chief Financial Officer of Command Audio Corporation from 1996 to 2011. Mr. Krakaris received a Bachelor of Commerce in Marketing and International Business from McGill University, and a M.B.A. from the University of California, Berkeley, Haas School of Business.- Emmanuel Krakaris自2018年10月起担任我们的总裁，首席执行官，秘书和董事会成员。在Krakaris先生被任命为我们的总裁，首席执行官兼秘书之前，Krakaris先生于2018年4月至2018年5月担任董事会顾问，并于2018年6月至2018年9月担任我们的首席运营官。在加入我们之前，Krakaris先生于2014年8月至2018年2月担任Streetline，Inc.的首席执行官，并于2011年至2014年8月担任首席财务官兼首席运营官。从1996年到2011年，Krakaris先生还担任Command Audio Corporation的首席财务官。Krakaris先生获得了麦吉尔大学市场营销和国际商务的商业学士学位，以及加州大学伯克利分校哈斯商学院的工商管理硕士学位。
- Emmanuel Krakaris,has served as Augmedix, Inc. President, Chief Executive Officer, Secretary and as a member of Augmedix, Inc. board of directors since October 2018. Before Mr. Krakaris was appointed as Augmedix, Inc. President, Chief Executive Officer and Secretary, Mr. Krakaris served as an advisor to the board of directors from April 2018 to May 2018 and as Augmedix, Inc. Chief Operating Officer from June 2018 to September 2018. Prior to joining Augmedix, Inc. , Mr. Krakaris served as the Chief Executive Officer of Streetline, Inc. from August 2014 to February 2018 and as Chief Financial Officer and Chief Operating Officer from 2011 to August 2014. Mr. Krakaris also served as Chief Financial Officer of Command Audio Corporation from 1996 to 2011. Mr. Krakaris received a Bachelor of Commerce in Marketing and International Business from McGill University, and a M.B.A. from the University of California, Berkeley, Haas School of Business.
- Sandra Breber
Sandra Breber自2019年3月起担任我们的首席运营官，在此之前，她于2018年11月至2019年3月担任公司顾问。在加入我们之前，布雷伯女士于2018年11月至2019年3月担任Snipp Interactive，Inc.的顾问。布雷伯女士还于2013年4月至2018年11月担任Ziploop，Inc.的总裁兼联合创始人。在她职业生涯的早期，Breber女士担任Arthur Andersen L.L.P.的合伙人。Breber女士拥有麦吉尔大学会计和金融商业学士学位。
Sandra Breber,has served as Augmedix, Inc. Chief Operating Officer since March 2019, and prior to that served as an advisor to the Company from November 2018 to March 2019. Prior to joining Augmedix, Inc. , Ms. Breber served as advisor to Snipp Interactive, Inc. from November 2018 to March 2019. Ms. Breber also served as President and Co-founder of Ziploop, Inc., from April 2013 to November 2018. Earlier in her career, Ms. Breber served as a Partner at Arthur Andersen L.L.P. Ms. Breber holds a Bachelor of Commerce in Accounting and Finance from McGill University.- Sandra Breber自2019年3月起担任我们的首席运营官，在此之前，她于2018年11月至2019年3月担任公司顾问。在加入我们之前，布雷伯女士于2018年11月至2019年3月担任Snipp Interactive，Inc.的顾问。布雷伯女士还于2013年4月至2018年11月担任Ziploop，Inc.的总裁兼联合创始人。在她职业生涯的早期，Breber女士担任Arthur Andersen L.L.P.的合伙人。Breber女士拥有麦吉尔大学会计和金融商业学士学位。
- Sandra Breber,has served as Augmedix, Inc. Chief Operating Officer since March 2019, and prior to that served as an advisor to the Company from November 2018 to March 2019. Prior to joining Augmedix, Inc. , Ms. Breber served as advisor to Snipp Interactive, Inc. from November 2018 to March 2019. Ms. Breber also served as President and Co-founder of Ziploop, Inc., from April 2013 to November 2018. Earlier in her career, Ms. Breber served as a Partner at Arthur Andersen L.L.P. Ms. Breber holds a Bachelor of Commerce in Accounting and Finance from McGill University.
- Saurav Chatterjee
Saurav Chatterjee自2020年11月起担任我们的首席技术官。在加入我们之前，查特吉先生于2019年11月至2020年11月担任Lumiata，Inc.的工程副总裁。Chatterjee先生还于2014年5月至2019年10月担任Asurion，Inc.的高级总监兼对话AI负责人。从2010年11月到2014年4月，他曾担任Visa公司的首席架构师，在那里他曾开发Visa Checkout公司。Chatterjee先生拥有加州大学伯克利分校的电气工程和计算机科学学士学位，以及卡内基梅隆大学的计算机工程博士学位。
Saurav Chatterjee,has served as Augmedix, Inc. Chief Technology Officer since November 2020. Prior to joining Augmedix, Inc. , Mr. Chatterjee served as the Vice President of Engineering at Lumiata, Inc., from November 2019 to November 2020. Mr. Chatterjee also served as the Senior Director and Head Conversational AI at Asurion, Inc., from May 2014 to October 2019. From November 2010 to April 2014 Mr. Chatterjee was Chief Architect at Visa, where he developed Visa Checkout. Mr. Chatterjee holds a B.A. in Electrical Engineering and Computer Science from the University of California, Berkeley, and a PhD in Computer Engineering from Carnegie Mellon University.- Saurav Chatterjee自2020年11月起担任我们的首席技术官。在加入我们之前，查特吉先生于2019年11月至2020年11月担任Lumiata，Inc.的工程副总裁。Chatterjee先生还于2014年5月至2019年10月担任Asurion，Inc.的高级总监兼对话AI负责人。从2010年11月到2014年4月，他曾担任Visa公司的首席架构师，在那里他曾开发Visa Checkout公司。Chatterjee先生拥有加州大学伯克利分校的电气工程和计算机科学学士学位，以及卡内基梅隆大学的计算机工程博士学位。
- Saurav Chatterjee,has served as Augmedix, Inc. Chief Technology Officer since November 2020. Prior to joining Augmedix, Inc. , Mr. Chatterjee served as the Vice President of Engineering at Lumiata, Inc., from November 2019 to November 2020. Mr. Chatterjee also served as the Senior Director and Head Conversational AI at Asurion, Inc., from May 2014 to October 2019. From November 2010 to April 2014 Mr. Chatterjee was Chief Architect at Visa, where he developed Visa Checkout. Mr. Chatterjee holds a B.A. in Electrical Engineering and Computer Science from the University of California, Berkeley, and a PhD in Computer Engineering from Carnegie Mellon University.
- Jonathan Hawkins
Jonathan Hawkins自2019年4月起担任我们的首席收益官。在加入我们之前，Hawkins先生于2017年10月至2019年4月担任Spry Health，Inc.的业务发展高级副总裁兼销售与市场营销，该公司是一家医疗保健数据分析提供商，可识别慢性病患者临床恶化的早期迹象。Hawkins先生还是The Batchery的创始投资者和顾问，该公司是一家创业孵化器和加速器。在此之前，Hawkins先生于2016年5月至2017年10月担任MedeAnalytics，Inc.业务开发和销售副总裁。从2015年11月到2016年3月，Hawkins先生担任Cal Index的顾问，这是一家非营利性的健康信息交易所。Hawkins先生拥有斯坦福大学国际关系学士学位和哈佛商学院工商管理硕士学位。
Jonathan Hawkins,has served as Augmedix, Inc. Chief Revenue Officer since April 2019. Prior to joining Augmedix, Inc. , Mr. Hawkins was Senior Vice President of Business Development, Sales and Marketing for Spry Health, Inc., a healthcare data analytics provider that identifies early signs of clinical deterioration in chronically-ill patients, from October 2017 to April 2019. Mr. Hawkins was also a Founding Investor and Advisor to The Batchery, a startup incubator and accelerator. Prior to that, Mr. Hawkins was Vice President of Business Development and Sales for MedeAnalytics, Inc., from May 2016 to October 2017. From November 2015 to March 2016, Mr. Hawkins served as a consultant to Cal INDEX, a non-profit health information exchange. Mr. Hawkins holds a B.A. in International Relations from Stanford University, and an M.B.A. from Harvard Business School.- Jonathan Hawkins自2019年4月起担任我们的首席收益官。在加入我们之前，Hawkins先生于2017年10月至2019年4月担任Spry Health，Inc.的业务发展高级副总裁兼销售与市场营销，该公司是一家医疗保健数据分析提供商，可识别慢性病患者临床恶化的早期迹象。Hawkins先生还是The Batchery的创始投资者和顾问，该公司是一家创业孵化器和加速器。在此之前，Hawkins先生于2016年5月至2017年10月担任MedeAnalytics，Inc.业务开发和销售副总裁。从2015年11月到2016年3月，Hawkins先生担任Cal Index的顾问，这是一家非营利性的健康信息交易所。Hawkins先生拥有斯坦福大学国际关系学士学位和哈佛商学院工商管理硕士学位。
- Jonathan Hawkins,has served as Augmedix, Inc. Chief Revenue Officer since April 2019. Prior to joining Augmedix, Inc. , Mr. Hawkins was Senior Vice President of Business Development, Sales and Marketing for Spry Health, Inc., a healthcare data analytics provider that identifies early signs of clinical deterioration in chronically-ill patients, from October 2017 to April 2019. Mr. Hawkins was also a Founding Investor and Advisor to The Batchery, a startup incubator and accelerator. Prior to that, Mr. Hawkins was Vice President of Business Development and Sales for MedeAnalytics, Inc., from May 2016 to October 2017. From November 2015 to March 2016, Mr. Hawkins served as a consultant to Cal INDEX, a non-profit health information exchange. Mr. Hawkins holds a B.A. in International Relations from Stanford University, and an M.B.A. from Harvard Business School.
- Paul Ginocchio
Paul Ginocchio自2020年7月起担任我们的首席财务官。在加入我们之前，Ginocchio先生于2019年12月至2020年6月担任多家技术公司的独立战略顾问。Ginocchio先生曾于2017年1月至2019年9月担任劳动力数据和分析公司Brightfield Strategies LLC.的首席财务官。在此之前，Ginocchio先生于2016年9月至2016年12月担任多家公司的行业顾问和临时首席财务官。从1998年11月到2016年5月，Ginocchio先生担任首席分析师，然后担任德意志银行信息与商业服务股权研究的董事总经理。Ginocchio先生拥有北卡罗来纳州立大学的经济和商业管理学士学位，以及印第安纳大学凯利商学院的金融工商管理硕士学位。
Paul Ginocchio,has served as Augmedix, Inc. Chief Financial Officer since July 2020. Prior to joining Augmedix, Inc. , from December 2019 to June 2020, Mr. Ginocchio served as an independent strategic advisor to multiple technology companies. Mr. Ginocchio previously served as Chief Financial Officer of Brightfield Strategies LLC., a workforce data and analytics company, from January 2017 to September 2019. Prior to that, Mr. Ginocchio served as an industry consultant and interim Chief Financial Officer from September 2016 to December 2016 for various companies. From November 1998 to May 2016, Mr. Ginocchio was Lead Analyst, then Managing Director of Information & Business Services Equity Research at Deutsche Bank AG. Mr. Ginocchio holds B.A. in Economics & Business Management from North Carolina State University, and a M.B.A. in Finance from Indiana University Kelley School of Business.- Paul Ginocchio自2020年7月起担任我们的首席财务官。在加入我们之前，Ginocchio先生于2019年12月至2020年6月担任多家技术公司的独立战略顾问。Ginocchio先生曾于2017年1月至2019年9月担任劳动力数据和分析公司Brightfield Strategies LLC.的首席财务官。在此之前，Ginocchio先生于2016年9月至2016年12月担任多家公司的行业顾问和临时首席财务官。从1998年11月到2016年5月，Ginocchio先生担任首席分析师，然后担任德意志银行信息与商业服务股权研究的董事总经理。Ginocchio先生拥有北卡罗来纳州立大学的经济和商业管理学士学位，以及印第安纳大学凯利商学院的金融工商管理硕士学位。
- Paul Ginocchio,has served as Augmedix, Inc. Chief Financial Officer since July 2020. Prior to joining Augmedix, Inc. , from December 2019 to June 2020, Mr. Ginocchio served as an independent strategic advisor to multiple technology companies. Mr. Ginocchio previously served as Chief Financial Officer of Brightfield Strategies LLC., a workforce data and analytics company, from January 2017 to September 2019. Prior to that, Mr. Ginocchio served as an industry consultant and interim Chief Financial Officer from September 2016 to December 2016 for various companies. From November 1998 to May 2016, Mr. Ginocchio was Lead Analyst, then Managing Director of Information & Business Services Equity Research at Deutsche Bank AG. Mr. Ginocchio holds B.A. in Economics & Business Management from North Carolina State University, and a M.B.A. in Finance from Indiana University Kelley School of Business.
- Ian Shakil
Ian Shakil是我们的创始人，自2013年4月起担任我们的董事会成员。他曾于2018年8月至2020年9月担任我们的董事会主席，自2018年10月以来一直担任我们的首席战略官。在此之前，Shakil先生于2013年4月至2018年10月担任我们的首席执行官。Shakil先生自2019年5月以来还担任爱德华兹生命科学公司的顾问。Shakil先生在杜克大学获得生物医学工程学士学位，并在斯坦福大学商学院获得工商管理硕士学位。我们相信Shakil先生有资格在我们的董事会任职，因为他是我们的创始人和前首席执行官，以及他在医疗保健行业的业务和技术经验。
Ian Shakil,is Augmedix, Inc. founder and has been a member of Augmedix, Inc. board of directors since April 2013. He previously served as Chairman of Augmedix, Inc. board of directors from August 2018 to September 2020 and has served as Augmedix, Inc. Chief Strategy Officer since October 2018. Prior to that, Mr. Shakil served as Augmedix, Inc. Chief Executive Officer from April 2013 to October 2018. Mr. Shakil has also served as Advisor to Edwards Lifesciences Corporation since May 2019. Mr. Shakil has a B.S.E. in Biomedical Engineering from Duke University, and an M.B.A. from Stanford University Graduate School of Business.- Ian Shakil是我们的创始人，自2013年4月起担任我们的董事会成员。他曾于2018年8月至2020年9月担任我们的董事会主席，自2018年10月以来一直担任我们的首席战略官。在此之前，Shakil先生于2013年4月至2018年10月担任我们的首席执行官。Shakil先生自2019年5月以来还担任爱德华兹生命科学公司的顾问。Shakil先生在杜克大学获得生物医学工程学士学位，并在斯坦福大学商学院获得工商管理硕士学位。我们相信Shakil先生有资格在我们的董事会任职，因为他是我们的创始人和前首席执行官，以及他在医疗保健行业的业务和技术经验。
- Ian Shakil,is Augmedix, Inc. founder and has been a member of Augmedix, Inc. board of directors since April 2013. He previously served as Chairman of Augmedix, Inc. board of directors from August 2018 to September 2020 and has served as Augmedix, Inc. Chief Strategy Officer since October 2018. Prior to that, Mr. Shakil served as Augmedix, Inc. Chief Executive Officer from April 2013 to October 2018. Mr. Shakil has also served as Advisor to Edwards Lifesciences Corporation since May 2019. Mr. Shakil has a B.S.E. in Biomedical Engineering from Duke University, and an M.B.A. from Stanford University Graduate School of Business.